|
1
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gonzalvez F, Schug ZT, Houtkooper RH,
MacKenzie ED, Brooks DG, Wanders RJ, Petit PX, Vaz FM and Gottlieb
E: Cardiolipin provides an essential activating platform for
caspase-8 on mitochondria. J Cell Biol. 183:681–696. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hooper LV, Littman DR and Macpherson AJ:
Interactions between the microbiota and the immune system. Science.
336:1268–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ivanov II and Honda K: Intestinal
commensal microbes as immune modulators. Cell Host Microbe.
12:496–508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McAleer JP and Kolls JK: Maintaining
poise: Commensal microbiota calibrate interferon responses.
Immunity. 37:10–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jernberg C, Löfmark S, Edlund C and
Jansson JK: Long-term ecological impacts of antibiotic
administration on the human intestinal microbiota. ISME J. 1:56–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Korpela K, Salonen A, Virta LJ, Kekkonen
RA, Forslund K, Bork P and de Vos WM: Intestinal microbiome is
related to lifetime antibiotic use in Finnish pre-school children.
Nat Commun. 7:104102016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Becattini S, Taur Y and Pamer EG:
Antibiotic-induced changes in the intestinal microbiota and
disease. Trends Mol Med. 22:458–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sivan A, Corrales L, Hubert N, Williams
JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B,
Alegre ML, et al: Commensal Bifidobacterium promotes antitumor
immunity and facilitates anti-PD-L1 efficacy. Science.
350:1084–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vétizou M, Pitt JM, Daillére R, Lepage P,
Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong
CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on
the gut microbiota. Science. 350:1079–1084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Derosa L, Routy B, Enot D, Baciarello G,
Massard C, Loriot Y, Fizazi K, Escudier BJ, Zitvogel L and Albiges
L: Impact of antibiotics on outcome in patients with metastatic
renal cell carcinoma treated with immune checkpoint inhibitors. J
Clin Oncol. 35:462. 2017. View Article : Google Scholar
|
|
16
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ji RR, Chasalow SD, Wang L, Hamid O,
Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M,
Siemers NO, et al: An immune-active tumor microenvironment favors
clinical response to ipilimumab. Cancer Immunol Immunother.
61:1019–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gajewski TF, Louahed J and Brichard VG:
Gene signature in melanoma associated with clinical activity: A
potential clue to unlock cancer immunotherapy. Cancer J.
16:399–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Belkaid Y and Hand TW: Role of the
microbiota in immunity and inflammation. Cell. 157:121–141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kostic AD, Gevers D, Pedamallu CS, Michaud
M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et
al: Genomic analysis identifies association of Fusobacterium with
colorectal carcinoma. Genome Res. 22:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rowland IR: The role of the
gastrointestinal microbiota in colorectal cancer. Curr Pharm Des.
15:1524–1527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu Q, Gao R, Wu W and Qin H: The role of
gut microbiota in the pathogenesis of colorectal cancer. Tumour
Biol. 34:1285–1300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen HM, Yu YN, Wang JL, Lin YW, Kong X,
Yang CQ, Yang L, Liu ZJ, Yuan YZ, Liu F, et al: Decreased dietary
fiber intake and structural alteration of gut microbiota in
patients with advanced colorectal adenoma. Am J Clin Nutr.
97:1044–1052. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang
X, Jia W, Cai S and Zhao L: Structural segregation of gut
microbiota between colorectal cancer patients and healthy
volunteers. ISME J. 6:320–329. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peek RM Jr and Blaser MJ: Helicobacter
pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer.
2:28–37. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang Y, Wang X, Huycke T, Moore DR,
Lightfoot SA and Huycke MM: Colon macrophages polarized by
commensal bacteria cause colitis and cancer through the bystander
effect. Transl Oncol. 6:596–606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Castellarin M, Warren RL, Freeman JD,
Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P,
Allen-Vercoe E, Moore RA and Holt RA: Fusobacterium nucleatum
infection is prevalent in human colorectal carcinoma. Genome Res.
22:299–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McIntosh GH, Royle PJ and Playne MJ: A
probiotic strain of L. acidophilus reduces DMH-induced large
intestinal tumors in male Sprague-Dawley rats. Nutr Cancer.
35:153–159. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sonnenberg GF and Artis D: Innate lymphoid
cell interactions with microbiota: Implications for intestinal
health and disease. Immunity. 37:601–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu S, Shin J, Zhang G, Cohen M, Franco A
and Sears CL: The Bacteroides fragilis toxin binds to a specific
intestinal epithelial cell receptor. Infect Immun. 74:5382–5390.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu S, Rhee KJ, Albesiano E, Rabizadeh S,
Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, et al: A
human colonic commensal promotes colon tumorigenesis via activation
of T helper type 17 T cell responses. Nat Med. 15:1016–1022. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matson V, Fessler J, Bao R, Chongsuwat T,
Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome
is associated with anti-PD-1 efficacy in metastatic melanoma
patients. Science. 359:104–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gopalakrishnan V, Spencer CN, Nezi L,
Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman
K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1
immunotherapy in melanoma patients. Science. 359:97–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaderbhai C, Richard C, Fumet JD, Aarnink
A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R
and Ghiringhelli F: Antibiotic use does not appear to influence
response to nivolumab. Anticancer Res. 37:3195–3200.
2017.PubMed/NCBI
|
|
37
|
Jackson MA, Goodrich JK, Maxan ME,
Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE and
Bell JT: Proton pump inhibitors alter the composition of the gut
microbiota. Gut. 65:749–756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang EY, Inoue T, Leone VA, Dalal S, Touw
K, Wang Y, Musch MW, Theriault B, Higuchi K, Donovan S, et al:
Using corticosteroids to reshape the gut microbiome: Implications
for inflammatory bowel diseases. Inflamm Bowel Dis. 21:963–972.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rogers MAM and Aronoff DM: The influence
of non-steroidal anti-inflammatory drugs on the gut microbiome.
Clin Microbiol Infect. 22:178 e171–178 e179. 2016. View Article : Google Scholar
|
|
40
|
Flowers SA, Evans SJ, Ward KM, McInnis MG
and Ellingrod VL: Interaction between atypical antipsychotics and
the gut microbiome in a bipolar disease cohort. Pharmacotherapy.
37:261–267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Imhann F, Bonder MJ, Vich Vila A, Fu J,
Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC,
Harmsen HJ, et al: Proton pump inhibitors affect the gut
microbiome. Gut. 65:740–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Derosa L, Hellmann MD, Spaziano M,
Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC,
Chaft JE, et al: Negative association of antibiotics on clinical
activity of immune checkpoint inhibitors in patients with advanced
renal cell and non-small-cell lung cancer. Ann Oncol. 29:1437–1444.
2018. View Article : Google Scholar : PubMed/NCBI
|
